Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its generic version of Menarini’s brivudine. This approval signifies that Warrant Pharma’s version of the drug has successfully passed the generic quality consistency evaluation (GQCE) and is now the first generic brivudine approved in China.
Properties and Uses of Brivudine
Brivudine is a uridine derivative and nucleoside analog known for its pro-apoptotic and chemosensitizing properties. It is utilized as an anti-viral drug and was initially approved in Europe in March 2002 for the early treatment of adult patients with acute herpes zoster who possess normal immune function.
Competition in the Generic Brivudine Market
In the Chinese market, CR Double-crane’s generic version of brivudine is also awaiting a regulatory decision, with the aim of becoming the second approved generic option. The approval of Warrant Pharma’s generic brivudine is a significant step forward in providing more affordable treatment options for patients in China.-Fineline Info & Tech
